ArticleScientific reports2025
Unveiling Calotropis procera's promising wound healing secrets by QSAR, molecular docking, DFT and ADMET profiling.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multiscale Computational and Pharmacophore-Based Screening of ALK Inhibitors with Experimental Validation.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research work comprises the computational analysis of natural compounds from Calotropis procera analyzed on the basis of their wound healing properties. 3D Quantitative structure activity relationship (QSAR) models were generated with statistical validation which was followed by leading compound candidates. This analytical technique was carried out for the evaluation of active compounds by correlation of structural parameters. Previously isolated natural compounds were selected on the basis of their in-vivo and in-vitro studies. After 3D-QSAR analysis, molecular docking procedure was performed on the active compounds against wound healing proteins (PDB: 6SMA, 5A8Y) and their binding scores were analyzed for the evaluation of binding interaction of Protein-Ligand complexes. Comparative analysis was also carried out by comparing the docking results of natural compounds and FDA approved antibiotics Cephalexin, Dicloxacillin, and Levofloxacin. After docking, Re-docking was also performed as an additional cross analysis technique for validation of the docking results. DFT study was carried out to reveal molecular activity by evaluation of quantum molecular properties. Hence, results revealed that Stigmasterol (12) is hit compound with better results than standard drugs Cephalexin and Levofloxacin. These derived results in this study provide significant information for wound healer drug-designing by using Stigmtasterol as natural compound having better wound healing property. The analysis suggested that the proposed hit compound exhibits the potential drug attribute, which indicates the suitability for future investigation to help treat the serious wounds or injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.